CBT as reported
Cabot Corporation reported $3.58B of revenue over the trailing twelve months, −8.5% on the year before. 11 reported series are charted on this page, each one as filed.
$3.58B
Revenue, trailing twelve months · to Q2 2026 · −8.5% against the twelve months before
- Net Income
- $285M
Net Income · −34% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- $432M
Free Cash Flow · +37% year on year · trailing twelve months to Q2 2026
- Op Margin
- 16%
Op Margin · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $3.58B | −8.5% | Q2 2026 |
| Net Income | $285M | −34% | Q2 2026 |
| EPS | $5.30 | −31% | Q2 2026 |
| Gross Margin | 25% | n/a | Q2 2026 |
| Op Margin | 16% | n/a | Q2 2026 |
| Net Margin | 8.0% | n/a | Q2 2026 |
| ROE | 22% | n/a | Q2 2026 |
| ROA | 8.8% | n/a | Q2 2026 |
| ROIC | 19% | n/a | Q2 2026 |
| Free Cash Flow | $432M | +37% | Q2 2026 |
| P/E | 16.0 | n/a | today |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Cabot Corporation (CBT) - Revenue & ProfitRevenue & ProfitCabot Corporation (CBT)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Specialty Chemicals
Ranks #24 of 36 by Smart Score